146 related articles for article (PubMed ID: 26860847)
1. Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim--correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF.
Lehmacher W; Klasser M; Duering A
Support Care Cancer; 2016 May; 24(5):1935-1937. PubMed ID: 26860847
[No Abstract] [Full Text] [Related]
2. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21.
Lei MM; Watson AN; Abramson JS
Leuk Lymphoma; 2020 Dec; 61(12):2998-3001. PubMed ID: 32686543
[No Abstract] [Full Text] [Related]
6. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
7. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years.
Edelsberg J; Weycker D; Bensink M; Bowers C; Lyman GH
Curr Med Res Opin; 2020 Mar; 36(3):483-495. PubMed ID: 31834830
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T; Lück A; Schulz H; Harde J; Losem C; Grebhardt S; Wolff T; Potthoff K; Müller U; Zaiss M; Kurbacher CM
Curr Med Res Opin; 2019 Jul; 35(7):1127-1138. PubMed ID: 30557099
[No Abstract] [Full Text] [Related]
10. The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
Holubec L; Polivka J; Lisnerova L; Kubikova T; Safanda M
In Vivo; 2017; 31(3):303-306. PubMed ID: 28438855
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
12. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
13. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.
Cornes P; Gascon P; Chan S; Hameed K; Mitchell CR; Field P; Latymer M; Arantes LH
Adv Ther; 2018 Nov; 35(11):1816-1829. PubMed ID: 30298233
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
Younis T; Rayson D; Jovanovic S; Skedgel C
Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
[TBL] [Abstract][Full Text] [Related]
17. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review.
Bohlius J; Reiser M; Schwarzer G; Engert A
Br J Haematol; 2003 Aug; 122(3):413-23. PubMed ID: 12877668
[TBL] [Abstract][Full Text] [Related]
18. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
20. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
